Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors

Zheng, Qingyuan; Yu, Xiao; Zhang, Menggang; Zhang, Shuijun; Guo, Wenzhi; He, Yuting

doi:10.3389/fcell.2021.750084

Cited by 5 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LEF1-AS1 is up-regulated in many diseases, such as cell lung cancer and esophageal squamous cell carcinoma, and promotes cell proliferation and migration [50][51][52][53]. LEF1-AS1 is a transcript annotated on the opposite strand of the coding gene LEF1/TCF1 (lymphoid enhancer factor/ T-cell factor) and induces the expression of LEF1 mRNA epigenetically, by regulating H3K4 trimethylation in LEF1 promoter region [54].…”

Section: Discussionmentioning

confidence: 99%

HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the Peripheral Blood Mononuclear Cells of COVID-19 patients

GRECO,

MADE’,

MUTOLI

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Even after 3 years from SARS-CoV-2 identification, COVID-19 is still a persistent and dangerous global infectious disease. Significant improvements in our understanding of the disease pathophysiology have now been achieved. Nonetheless, reliable and accurate biomarkers for the early stratification of COVID-19 severity are still lacking. Long noncoding RNAs (LncRNAs) are ncRNAs longer than 200 nucleotides, regulating the transcription and translation of protein‐coding genes and they can be found in the peripheral blood, thus holding a promising biomarker potential. Specifically, peripheral blood mononuclear cells (PBMCs) have emerged as a source of indirect biomarkers mirroring the conditions of tissues: they include monocytes, B and T lymphocytes, and natural killer T cells (NKT), being highly informative for immune-related events. Methods We profiled by RNA-Sequencing a panel of 2,906 lncRNAs to investigate their modulation in PBMCs of a pilot group of COVID-19 patients, followed by qPCR validation in 111 hospitalized COVID-19 patients. Results The levels of four lncRNAs were found to be decreased in association with COVID-19 mortality and disease severity: HLA Complex Group 18-242 and -244 (HCG18-242 and HCG18-244), Lymphoid Enhancer Binding Factor 1-antisense 1 (LEF1-AS1) and lncCEACAM21 (i.e. ENST00000601116.5, a lncRNA in the CEACAM21 locus). Interestingly, these deregulations were confirmed in an independent patient group of hospitalized patients and by the re-analysis of publicly available single-cell transcriptome datasets. The identified lncRNAs were expressed in all of the PBMC cell types and inversely correlated with the neutrophil/lymphocyte ratio (NLR), an inflammatory marker. In vitro, the expression of LEF1-AS1 and lncCEACAM21 was decreased upon THP-1 monocytes exposure to a relevant stimulus, hypoxia. Conclusion The identified COVID-19-lncRNAs are proposed as potential innovative biomarkers of COVID-19 severity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the Peripheral Blood Mononuclear Cells of COVID-19 patients

GRECO,

MADE’,

MUTOLI

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Several other non-coding RNAs have been demonstrated to serve a role in tumor development (136). The long non-coding lymph enhancer-binding factor 1-antisense RNA1 has been found to act as a tumor promoter in a number of malignant tumors; however, it acts as a tumor suppressor in myeloid cancer (137). Furthermore, circ0021205 is a non-coding circRNA that promotes cancer progression in cholangiocarcinoma and non-small cell lung cancer (NSCLC) (138).…”

Section: Stromal Cellsmentioning

confidence: 99%

Role of the tumor microenvironment in cancer hallmarks and targeted therapy (Review)

et al. 2022

View full text Add to dashboard Cite

Genetic alterations drive tumor onset and progression. However, the cross-talk between tumor cells and the benign components of the surrounding stroma can also promote the initiation, progression and metastasis of solid tumors. These cellular and non-cellular stromal components form the tumor microenvironment (TME), which co-evolves with tumor cells. Their dynamic and mutualistic interactions are currently considered to be among the distinctive hallmarks of cancer. Biochemical and physical cues from the TME serve an essential role in regulating tumor onset and progression. They are also associated with resistance to treatment and poor prognosis in patients with cancer. Therefore, a deep understanding of the TME is vital for developing potent anticancer therapeutics and improving patient outcomes. The present review aims to review the biology of both cellular and non-cellular constituents of the TME and novel findings regarding their contribution to core as well as emerging cancer hallmarks. The present review also describes key TME markers that are either targeted in interventional clinical trials or serve as promising potential anticancer therapies. Understanding TME components and their intercellular interactions is key toward identifying the mechanisms of progression and treatment resistance. Such understanding is of utmost significance for personalized and effective cancer therapy strategies.

show abstract

Beyond the genome: lncRNAs as regulators of the PI3K/AKT pathway in lung cancer

Almalki

2023

Pathology - Research and Practice

View full text Add to dashboard Cite

Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors

Cited by 5 publications

References 80 publications

HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the Peripheral Blood Mononuclear Cells of COVID-19 patients

HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the Peripheral Blood Mononuclear Cells of COVID-19 patients

Role of the tumor microenvironment in cancer hallmarks and targeted therapy (Review)

Beyond the genome: lncRNAs as regulators of the PI3K/AKT pathway in lung cancer

Contact Info

Product

Resources

About